Previous Article | Next Article ![]()
Journal of Virology, October 1999, p. 8541-8548, Vol. 73, No. 10
Laboratory of Viral and Immunopathogenesis of
Diabetes,
Received 18 March 1999/Accepted 16 June 1999
Macrophages comprise the major population of cells infiltrating
pancreatic islets during the early stages of infection in DBA/2 mice by
the D variant of encephalomyocarditis virus (EMC-D virus). Inactivation
of macrophages prior to viral infection almost completely prevents
EMC-D virus-induced diabetes. This investigation was initiated to
determine whether a tyrosine kinase signalling pathway might be
involved in the activation of macrophages by EMC-D virus infection and
whether tyrosine kinase inhibitors might, therefore, abrogate EMC-D
virus-induced diabetes in vivo. When isolated macrophages were infected
with EMC-D virus, inducible nitric oxide synthase mRNA was expressed
and nitric oxide was subsequently produced. Treatment of macrophages
with the tyrosine kinase inhibitor tyrphostin AG126, but not tyrphostin
AG556, prior to EMC-D virus infection blocked the production of nitric
oxide. The infection of macrophages with EMC-D virus also resulted in the activation of the mitogen-activated protein kinases (MAPKs) p42MAPK/ERK2/p44MAPK/ERK1, p38MAPK,
and p46/p54JNK. In accord with the greater potency of AG126
than of AG556 in blocking EMC-D virus-mediated macrophage activation,
the incidence of diabetes in EMC-D virus-infected mice treated with
AG126 (25%) was much lower than that in AG556-treated (75%) or
vehicle-treated (88%) control mice. We conclude that EMC-D
virus-induced activation of macrophages resulting in
macrophage-mediated
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Prevention of Encephalomyocarditis Virus-Induced Diabetes in Mice
by Inhibition of the Tyrosine Kinase Signalling Pathway and
Subsequent Suppression of Nitric Oxide Production in
Macrophages
-cell destruction can be prevented by the
inhibition of a tyrosine kinase signalling pathway involved in
macrophage activation.
*
Corresponding author. Mailing address: Laboratory of
Viral Immunopathogenesis of Diabetes, Julia McFarlane Diabetes Research Centre, Faculty of Medicine, University of Calgary, 3330 Hospital Dr.
NW, Calgary, Alberta, Canada T2N 4N1. Phone: (403) 220-4569. Fax: (403)
270-7526. E-mail: yoon{at}ucalgary.ca.
Journal of Virology, October 1999, p. 8541-8548, Vol. 73, No. 10
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
| J. Bacteriol. | Mol. Cell. Biol. | Microbiol. Mol. Biol. Rev. |
|---|
| Clin. Vaccine Immunol. | ALL ASM JOURNALS |
|---|